Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice for Nonclinical Laboratory Studies

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-1671]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice for Nonclinical Laboratory Studies

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES:

Submit written comments (including recommendations) on the collection of information by December 31, 2020.

ADDRESSES:

To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to

https://www.reginfo.gov/public/do/PRAMain.

Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0119. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:

Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733,

PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Good Laboratory Practice for Nonclinical Laboratory Studies—21 CFR Part 58

OMB Control Number 0910-0119—Extension

Sections 409, 505, 512, and 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 348, 355, 360b, and 360e) and related statutes require manufacturers of food additives, human drugs and biological products, animal drugs, and medical devices to demonstrate the safety and utility of their product by submitting applications to FDA for research or marketing permits. Such applications contain, among other important items, full reports of all studies done to demonstrate product safety in man and/or other animals. In order to ensure adequate quality control for these studies and to provide an adequate degree of consumer protection, the Agency issued good laboratory practice (GLP) regulations for nonclinical laboratory studies in part 58 (21 CFR part 58). The regulations specify minimum standards for the proper conduct of safety testing and contain sections on facilities, personnel, equipment, standard operating procedures (SOPs), test and control articles, quality assurance, protocol and conduct of a safety study, records and reports, and laboratory disqualification,

and include information collection provisions.

Part 58 requires testing facilities engaged in conducting toxicological studies to retain, and make available to regulatory officials, records regarding compliance with GLPs. Records are maintained on file at each testing facility and examined there periodically by FDA inspectors. The GLP regulations require that, for each nonclinical laboratory study, a final report be prepared that documents the results of quality assurance unit inspections, test and control article characterization, testing of mixtures of test and control articles with carriers, and an overall interpretation of nonclinical laboratory studies. The GLP regulations also require written records pertaining to: (1) Personnel job descriptions and summaries of training and experience; (2) master schedules, protocols and amendments thereto, inspection reports, and SOPs; (3) equipment inspection, maintenance, calibration, and testing records; (4) documentation of feed and water analyses and animal treatments; (5) test article accountability records; and (6) study documentation and raw data.

In the

Federal Register

of July 24, 2020 (85 FR 44900), FDA published a 60-day notice requesting public comment on the proposed collection of information.

One comment was received that encouraged implementation of automated collection methods and analytical software to evaluate results. FDA appreciates this comment and continually seek ways to employ efficient collection methods using our limited resources. The comment suggested no revision to our burden estimate.

FDA estimates the burden of this information collection as follows:

Table 1—Estimated Annual Reporting Burden

1

21 CFR part

Number of

respondents

Number of

responses per

respondent

Total annual

responses

Average

burden per

response

Total hours

58.35(b)(7); Quality assurance unit

300

60.25

18,075

1

18,075

58.185; Reporting of nonclinical laboratory study results

300

60.25

18,075

27.65

499,774

Total

517,849

1

There are no capital costs or operating and maintenance costs associated with this collection of information.

Table 2—Estimated Annual Recordkeeping Burden

1

21 CFR part

Number of

recordkeepers

Number of records per recordkeeper

Total annual

records

Average

burden per

recordkeeping

Total hours

58.29(b); Personnel

300

20

6,000

.21 (13 minutes)

1,260

58.35(b)(1)-(6) and (c); Quality assurance unit

300

270.76

81,228

3.36

272,926

58.63(b) and (c); Maintenance and calibration of equipment

300

60

18,000

.09 (5 minutes)

1,620

58.81(a)-(c); SOPs

300

301.80

90,540

.14 (8 minutes)

12,676

58.90(c) and (g); Animal care

300

62.70

18,810

.13 (8 minutes)

2,445

58.105(a) and (b); Test and control article characterization

300

5

1,500

11.8

17,700

58.107(d); Test and control article handling

300

1

300

4.25

1,275

58.113(a); Mixtures of articles with carriers

300

15.33

4,599

6.8

31,273

58.120; Protocol

300

15.38

4,614

32.7

150,878

58.195; Retention of records

300

251.50

75,450

3.9

294,255

Total

786,308

1

There are no capital costs or operating and maintenance costs associated with this collection of information.

Based on a review of the information collection since our last request for OMB approval, FDA has made no adjustments to our burden estimate.

Dated: November 24, 2020.

Lauren K. Roth,

Acting Principal Associate Commissioner for Policy.

[FR Doc. 2020-26502 Filed 11-30-20; 8:45 am]

BILLING CODE 4164-01-P